Literature DB >> 21458841

The association between total urinary arsenic concentration and renal dysfunction in a community-based population from central Taiwan.

Jein-Wen Chen1, Hsiao-Yen Chen, Wan-Fen Li, Saou-Hsing Liou, Chien-Jen Chen, Jhuo-Han Wu, Shu-Li Wang.   

Abstract

Arsenic (As) is an important environmental toxicant that can cause cancer and cardiovascular disease, but the relationship between As exposure and renal dysfunction is not clear. The aim of this study is to examine the association between As exposure and renal dysfunction in a community-based population in central Taiwan. One thousand and forty-three subjects were recruited between 2002 and 2005. The risk for type 2 diabetes was increased by 2-fold (p<0.05) in subjects with total urinary As (U-As)>75 μg g(-1) creatinine as compared with subjects whose U-As was ≤ 35 μg g(-1) creatinine after the adjustment for potential confounders. The adjusted odds ratio for an abnormal β2 microglobulin (B2MG>0.154 mg L(-1)) was significantly higher in subjects with U-As>35 μg g(-1) creatinine as compared with the reference group adjusted for age, sex, living area, cigarette smoking, diabetes, and hypertension. The risk for abnormal B2MG and estimated glomerular filtration rate (eGFR<90 mL min(-1)(1.73 m(2))(-1)) was both increased around 2-fold (p<0.05) in subjects with U-As>75 μg g(-1) creatinine as compared with those with U-As ≤ 35 μg g(-1) creatinine adjusted for all the risk factors plus lead (Pb), cadmium and nickel. The prevalence of abnormal B2MG was 4.82 times higher in subjects with both over the median levels of U-As (85.1 μg L(-1)) and urinary Pb (18.9 μg L(-1)) as compared to both lower than the median (p<0.001). These results indicate that U-As might relate to renal dysfunction even other important risk factors were taken into account. Follow-up studies for causal inference are warranted.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21458841     DOI: 10.1016/j.chemosphere.2011.02.091

Source DB:  PubMed          Journal:  Chemosphere        ISSN: 0045-6535            Impact factor:   7.086


  30 in total

Review 1.  Cardiovascular effects of arsenic: clinical and epidemiological findings.

Authors:  Francesco Stea; Fabrizio Bianchi; Liliana Cori; Rosa Sicari
Journal:  Environ Sci Pollut Res Int       Date:  2013-09-10       Impact factor: 4.223

2.  Arsenic and Chronic Kidney Disease: A Systematic Review.

Authors:  Laura Zheng; Chin-Chi Kuo; Jeffrey Fadrowski; Jackie Agnew; Virginia M Weaver; Ana Navas-Acien
Journal:  Curr Environ Health Rep       Date:  2014-09-01

3.  Targeted metabolomics to understand the association between arsenic metabolism and diabetes-related outcomes: Preliminary evidence from the Strong Heart Family Study.

Authors:  Miranda J Spratlen; Maria Grau-Perez; Jason G Umans; Joseph Yracheta; Lyle G Best; Kevin Francesconi; Walter Goessler; Teodoro Bottiglieri; Mary V Gamble; Shelley A Cole; Jinying Zhao; Ana Navas-Acien
Journal:  Environ Res       Date:  2018-09-27       Impact factor: 6.498

4.  The association of urine arsenic with prevalent and incident chronic kidney disease: evidence from the Strong Heart Study.

Authors:  Laura Y Zheng; Jason G Umans; Fawn Yeh; Kevin A Francesconi; Walter Goessler; Ellen K Silbergeld; Karen Bandeen-Roche; Eliseo Guallar; Barbara V Howard; Virginia M Weaver; Ana Navas-Acien
Journal:  Epidemiology       Date:  2015-07       Impact factor: 4.822

5.  Arsenic metabolism and one-carbon metabolism at low-moderate arsenic exposure: Evidence from the Strong Heart Study.

Authors:  Miranda Jones Spratlen; Mary V Gamble; Maria Grau-Perez; Chin-Chi Kuo; Lyle G Best; Joseph Yracheta; Kevin Francesconi; Walter Goessler; Yasmin Mossavar-Rahmani; Meghan Hall; Jason G Umans; Amanda Fretts; Ana Navas-Acien
Journal:  Food Chem Toxicol       Date:  2017-05-04       Impact factor: 6.023

6.  2,3,5,6-Tetramethylpyrazine (TMP) down-regulated arsenic-induced heme oxygenase-1 and ARS2 expression by inhibiting Nrf2, NF-κB, AP-1 and MAPK pathways in human proximal tubular cells.

Authors:  Xuezhong Gong; Vladimir N Ivanov; Tom K Hei
Journal:  Arch Toxicol       Date:  2015-09-24       Impact factor: 5.153

7.  Arsenic exposure, diabetes prevalence, and diabetes control in the Strong Heart Study.

Authors:  Matthew O Gribble; Barbara V Howard; Jason G Umans; Nawar M Shara; Kevin A Francesconi; Walter Goessler; Ciprian M Crainiceanu; Ellen K Silbergeld; Eliseo Guallar; Ana Navas-Acien
Journal:  Am J Epidemiol       Date:  2012-10-24       Impact factor: 4.897

8.  The Association of Arsenic Exposure and Arsenic Metabolism With the Metabolic Syndrome and Its Individual Components: Prospective Evidence From the Strong Heart Family Study.

Authors:  Miranda J Spratlen; Maria Grau-Perez; Lyle G Best; Joseph Yracheta; Mariana Lazo; Dhananjay Vaidya; Poojitha Balakrishnan; Mary V Gamble; Kevin A Francesconi; Walter Goessler; Shelley A Cole; Jason G Umans; Barbara V Howard; Ana Navas-Acien
Journal:  Am J Epidemiol       Date:  2018-08-01       Impact factor: 4.897

9.  Arsenic exposure, inflammation, and renal function in Bangladeshi adults: effect modification by plasma glutathione redox potential.

Authors:  Brandilyn A Peters; Xinhua Liu; Megan N Hall; Vesna Ilievski; Vesna Slavkovich; Abu B Siddique; Shafiul Alam; Tariqul Islam; Joseph H Graziano; Mary V Gamble
Journal:  Free Radic Biol Med       Date:  2015-04-24       Impact factor: 7.376

10.  Tetramethylpyrazine (TMP) protects against sodium arsenite-induced nephrotoxicity by suppressing ROS production, mitochondrial dysfunction, pro-inflammatory signaling pathways and programed cell death.

Authors:  Xuezhong Gong; Vladimir N Ivanov; Mercy M Davidson; Tom K Hei
Journal:  Arch Toxicol       Date:  2014-06-25       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.